Skip to main content
SpringerLink
Log in

Lung Cancer

  • Chapter
  • First Online:
Pulmonomics: Omics Approaches for Understanding Pulmonary Diseases

  • 176 Accesses

Abstract

Lung cancer has a complex pathophysiology and is one of the leading causes of death all over the world. Cutting edge imaging modalities and omics approaches have improved the diagnosis, stratification, and staging of the disease. Different pathological drivers and probable biomarker candidates of lung cancer identified using different advanced omics tools have been documented. Several databases and bioinformatics tools designed to improve our understanding of the disease and enable downstream analyses have been mentioned in this chapter. The potential use of computational modelling and multi-omics data analyses in lung cancer have been discussed. The present therapeutic regime for lung cancer including surgical resection, chemotherapy, immunotherapy, and targeted therapy have also been highlighted in this chapter. Finally, the different research avenues that can be explored in the field of lung cancer have been discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adjei AA (2004) Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 5(Suppl 2):S51–S55

    Article  CAS  PubMed  Google Scholar 

  • Adrianzen Herrera D, Ashai N, Perez-Soler R, Cheng H (2019) Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expert Opin Pharmacother 20(1):95–102

    Article  CAS  PubMed  Google Scholar 

  • Ahmed N, Bezabeh T, Ijare OB, Myers R, Alomran R, Aliani M, Nugent Z, Banerji S, Kim J, Qing G et al (2016) Metabolic signatures of lung cancer in sputum and exhaled breath condensate detected by (1)H magnetic resonance spectroscopy: a feasibility study. Magn Reson Insights 9:29–35

    PubMed  PubMed Central  Google Scholar 

  • Ahmed N, Kidane B, Wang L, Nugent Z, Moldovan N, McElrea A, Shariati-Ievari S, Qing G, Tan L, Buduhan G et al (2022) Metabolic alterations in sputum and exhaled breath condensate of early stage non-small cell lung cancer patients after surgical resection: a pilot study. Front Oncol 12:874964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Akinboro O, Larkins E, Pai-Scherf LH, Mathieu LN, Ren Y, Cheng J, Fiero MH, Fu W, Bi Y, Kalavar S et al (2022) FDA approval summary: pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1-high NSCLC. Clin Cancer Res 28(11):2221–2228

    Article  CAS  PubMed  Google Scholar 

  • Alsagaby S, Ahmed AA, Rasheed Z, Althwab SA, Aljohani ASM, Alhumaydhi FA, Alhomaidan HT, Alkhamiss AS, Alkhowailed M, Alaqeel A et al (2022) Association of genetic polymorphisms in DNA repair genes ERCC2 Asp312Asn (rs1799793), ERCC2 Lys 751 Gln (rs13181), XRCC1 Arg399 Gln (rs25487) and XRCC3 Thr 241Met (rs861539) with the susceptibility of lung cancer in Saudi population. Nucleosides Nucleotides Nucleic Acids 41(5–6):530–554

    Article  CAS  PubMed  Google Scholar 

  • Ansari J, Shackelford RE, El-Osta H (2016) Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res 5(2):155–171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bakulski KM, Dou J, Lin N, London SJ, Colacino JA (2019) DNA methylation signature of smoking in lung cancer is enriched for exposure signatures in newborn and adult blood. Sci Rep 9(1):4576

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baldwin EL, Osheroff N (2005) Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5(4):363–372

    Article  CAS  PubMed  Google Scholar 

  • Baran K, Brzezianska-Lasota E (2021) Proteomic biomarkers of non-small cell lung cancer patients. Adv Respir Med 89(4):419–426

    Article  PubMed  Google Scholar 

  • Bekisz S, Geris L (2020) Cancer modeling: from mechanistic to data-driven approaches, and from fundamental insights. J Comput Sci:46

    Google Scholar 

  • Bhattacharya A, Cui Y (2016) SomamiR 2.0: a database of cancer somatic mutations altering microRNA-ceRNA interactions. Nucleic Acids Res 44(D1):D1005–D1010

    Article  CAS  PubMed  Google Scholar 

  • Bhattacharya A, Ziebarth JD, Cui Y (2013) SomamiR: a database for somatic mutations impacting microRNA function in cancer. Nucleic Acids Res 41(Database issue):D977–D982

    Article  CAS  PubMed  Google Scholar 

  • Bilimoria KY, Stewart AK, Winchester DP, Ko CY (2008) The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15(3):683–690

    Article  PubMed  PubMed Central  Google Scholar 

  • Bishop JF: Carboplatin/etoposide in small cell lung cancer. Oncology 1992, 49 Suppl 1:11–17; discussion 17–18

    Google Scholar 

  • Bourbonne V, Geier M, Schick U, Lucia F (2022) Multi-omics approaches for the prediction of clinical endpoints after immunotherapy in non-small cell lung cancer: a comprehensive review. Biomedicine 10(6)

    Google Scholar 

  • Bradford D, Larkins E, Mushti SL, Rodriguez L, Skinner AM, Helms WS, Price LSL, Zirkelbach JF, Li Y, Liu J et al (2021) FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res 27(8):2130–2135

    Article  CAS  PubMed  Google Scholar 

  • Bustos A, Pertusa A, Salinas JM, de la Iglesia-Vaya M (2020) PadChest: a large chest X-ray image dataset with multi-label annotated reports. Med Image Anal 66:101797

    Article  PubMed  Google Scholar 

  • Byun J, Schwartz AG, Lusk C, Wenzlaff AS, de Andrade M, Mandal D, Gaba C, Yang P, You M, Kupert EY et al (2018) Genome-wide association study of familial lung cancer. Carcinogenesis 39(9):1135–1140

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cai L, Lin S, Girard L, Zhou Y, Yang L, Ci B, Zhou Q, Luo D, Yao B, Tang H et al (2019) LCE: an open web portal to explore gene expression and clinical associations in lung cancer. Oncogene 38(14):2551–2564

    Article  CAS  PubMed  Google Scholar 

  • Cameron SJS, Lewis KE, Huws SA, Hegarty MJ, Lewis PD, Pachebat JA, Mur LAJ (2017) A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS One 12(5):e0177062

    Article  PubMed  PubMed Central  Google Scholar 

  • Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113–1120

    Article  Google Scholar 

  • Capasso A (2012) Vinorelbine in cancer therapy. Curr Drug Targets 13(8):1065–1071

    Article  CAS  PubMed  Google Scholar 

  • Carrola J, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L et al (2011) Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res 10(1):221–230

    Article  CAS  PubMed  Google Scholar 

  • Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, Sanchez-Carbayo M (2010) Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med 8:86

    Article  PubMed  PubMed Central  Google Scholar 

  • Cellina M, Ce M, Irmici G, Ascenti V, Khenkina N, Toto-Brocchi M, Martinenghi C, Papa S, Carrafiello G (2022) Artificial intelligence in lung cancer imaging: unfolding the future. Diagnostics (Basel) 12(11)

    Google Scholar 

  • Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401–404

    Article  PubMed  Google Scholar 

  • Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18(1):248–262

    Article  CAS  PubMed  Google Scholar 

  • Chen R, Hong Q, Jiang J, Chen X, Jiang Z, Wang J, Liu S, Duan S, Shi S (2017) AGTR1 promoter hypermethylation in lung squamous cell carcinoma but not in lung adenocarcinoma. Oncol Lett 14(4):4989–4994

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen L, Zeng H, Xiang Y, Huang Y, Luo Y, Ma X (2021) Histopathological images and multi-omics integration predict molecular characteristics and survival in lung adenocarcinoma. Front Cell Dev Biol 9:720110

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen AS, Liu H, Wu Y, Luo S, Patz EF Jr, Glass C, Su L, Du M, Christiani DC, Wei Q (2022) Genetic variants in DDO and PEX5L in peroxisome-related pathways predict non-small cell lung cancer survival. Mol Carcinog 61(7):619–628

    Article  CAS  PubMed  Google Scholar 

  • Cheung CHY, Juan HF (2017) Quantitative proteomics in lung cancer. J Biomed Sci 24(1):37

    Article  PubMed  PubMed Central  Google Scholar 

  • Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E (2016) Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol 78(1):1–12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M et al (2013) The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 26(6):1045–1057

    Article  PubMed  PubMed Central  Google Scholar 

  • Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6):713–718

    Article  CAS  PubMed  Google Scholar 

  • Coker EA, Mitsopoulos C, Tym JE, Komianou A, Kannas C, Di Micco P, Villasclaras Fernandez E, Ozer B, Antolin AA, Workman P et al (2019) canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Res 47(D1):D917–D922

    Article  CAS  PubMed  Google Scholar 

  • Das M, Padda SK, Weiss J, Owonikoko TK (2021) Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): insights for optimizing patient outcomes from an expert roundtable discussion. Adv Ther 38(11):5431–5451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • de Marinis F, Attili I, Gridelli C, Cecere F, Curcio C, Facciolo F, Spaggiari L (2022) Incorporating atezolizumab in the adjuvant setting of non-small cell lung cancer: key discussion points from an expert multidisciplinary panel by Italian Association of Thoracic Oncology. Front Oncol 12:971042

    Article  PubMed  PubMed Central  Google Scholar 

  • de Sousa CL, Monteiro G (2014) Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol 741:8–16

    Article  Google Scholar 

  • Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, Crujerias AB, Pio R, Montuenga LM, Zulueta J et al (2016) A novel epigenetic signature for early diagnosis in lung cancer. Clin Cancer Res 22(13):3361–3371

    Article  CAS  PubMed  Google Scholar 

  • Dingerdissen HM, Torcivia-Rodriguez J, Hu Y, Chang TC, Mazumder R, Kahsay R (2018) BioMuta and BioXpress: mutation and expression knowledgebases for cancer biomarker discovery. Nucleic Acids Res 46(D1):D1128–D1136

    Article  CAS  PubMed  Google Scholar 

  • Du H, Liu L, Liu H, Luo S, Patz EF Jr, Glass C, Su L, Du M, Christiani DC, Wei Q (2021) Genetic variants of DOCK2, EPHB1 and VAV2 in the natural killer cell-related pathway are associated with non-small cell lung cancer survival. Am J Cancer Res 11(5):2264–2277

    CAS  PubMed  PubMed Central  Google Scholar 

  • Duke ES, Stapleford L, Drezner N, Amatya AK, Mishra-Kalyani PS, Shen YL, Maxfield K, Fourie Zirkelbach J, Bi Y, Liu J et al (2022) FDA approval summary: mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. Clin Cancer Res

    Google Scholar 

  • Dumont-Leblond N, Veillette M, Racine C, Joubert P, Duchaine C (2021) Non-small cell lung cancer microbiota characterization: Prevalence of enteric and potentially pathogenic bacteria in cancer tissues. PLoS One 16(4):e0249832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dungo RT, Keating GM (2013) Afatinib: first global approval. Drugs 73(13):1503–1515

    Article  CAS  PubMed  Google Scholar 

  • Dunn DB (2020) Larotrectinib and entrectinib: TRK inhibitors for the treatment of pediatric and adult patients with NTRK gene fusion. J Adv Pract Oncol 11(4):418–423

    PubMed  PubMed Central  Google Scholar 

  • Duruisseaux M (2019) Lorlatinib: a new treatment option for ROS1-positive lung cancer. Lancet Oncol 20(12):1622–1623

    Article  PubMed  Google Scholar 

  • Durvalumab Durvalumab approval expanded to reduce risk of NSCLC progression. Oncol Times 40(6)

    Google Scholar 

  • Emaminejad N, Qian W, Guan Y, Tan M, Qiu Y, Liu H, Zheng B (2016) Fusion of quantitative image and genomic biomarkers to improve prognosis assessment of early stage lung cancer patients. IEEE Trans Biomed Eng 63(5):1034–1043

    Article  PubMed  Google Scholar 

  • Facchinetti F, Friboulet L (2018) Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start. Transl Lung Cancer Res 7(Suppl 2):S103–S106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fala L (2016) Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer. Am Health Drug Benefits 9(Spec Feature):119–122

    PubMed  PubMed Central  Google Scholar 

  • Feng X, Xie X, Zheng B, Peng C, Zhou H, Qin J (2018) The more potential performance of nidogen 2 methylation by tissue or plasma DNA over brichoalveolar lavage DNA in diagnosis of nonsmall cell lung cancer. J Cancer Res Ther 14(Supplement):S341–S346

    Article  CAS  PubMed  Google Scholar 

  • Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D (2016) Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 44:42–50

    Article  CAS  PubMed  Google Scholar 

  • Firdous S, Ghosh A, Saha S: BCSCdb: a database of biomarkers of cancer stem cells. Database (Oxford) 2022, 2022

    Google Scholar 

  • Forde PM, Ettinger DS (2013) Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 13(6):745–758

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Freeberg MA, Fromont LA, D'Altri T, Romero AF, Ciges JI, Jene A, Kerry G, Moldes M, Ariosa R, Bahena S et al (2022) The European Genome-phenome Archive in 2021. Nucleic Acids Res 50(D1):D980–D987

    Article  CAS  PubMed  Google Scholar 

  • Fuertes MA, Castilla J, Alonso C, Perez JM (2003) Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 10(3):257–266

    Article  CAS  PubMed  Google Scholar 

  • Furuse K (1992) Platinum/oral etoposide therapy in non-small cell lung cancer. Oncology 49(Suppl 1):63–69. discussion 70

    Article  PubMed  Google Scholar 

  • Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1

    Google Scholar 

  • Georgoulias V (2002) Docetaxel (taxotere) in the treatment of non-small cell lung cancer. Curr Med Chem 9(8):869–877

    Article  CAS  PubMed  Google Scholar 

  • Gomes S, Cavadas B, Ferreira JC, Marques PI, Monteiro C, Sucena M, Sousa C, Vaz Rodrigues L, Teixeira G, Pinto P et al (2019) Profiling of lung microbiota discloses differences in adenocarcinoma and squamous cell carcinoma. Sci Rep 9(1):12838

    Article  PubMed  PubMed Central  Google Scholar 

  • Gong J, Fan Y, Lu H (2021) Pulmonary enteric adenocarcinoma. Transl Oncol 14(8):101123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59(4):657–663

    Article  CAS  PubMed  Google Scholar 

  • Green MR, Kreisman H, Doll DC, Lyss AP, Clamon GH, Goutsou M, Perry MC, Propert KJ (1992) Carboplatin in non-small cell lung cancer: an update on the Cancer and Leukemia Group B experience. Semin Oncol 19(1 Suppl 2):44–49

    CAS  PubMed  Google Scholar 

  • Grutters JP, Pijls-Johannesma M, Ruysscher DD, Peeters A, Reimoser S, Severens JL, Lambin P, Joore MA (2010) The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev 36(6):468–476

    Article  PubMed  Google Scholar 

  • Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6(4):363–373

    Article  CAS  PubMed  Google Scholar 

  • Harel M, Lahav C, Jacob E, Dahan N, Sela I, Elon Y, Raveh Shoval S, Yahalom G, Kamer I, Zer A et al (2022) Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. J Immunother Cancer 10(6)

    Google Scholar 

  • Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, Altenberger C, Minichsdorfer C, Lang G, Dome B, End-Pfutzenreuter A et al (2012) Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res 18(6):1619–1629

    Article  CAS  PubMed  Google Scholar 

  • Heller G, Babinsky VN, Ziegler B, Weinzierl M, Noll C, Altenberger C, Mullauer L, Dekan G, Grin Y, Lang G et al (2013) Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis 34(3):513–521

    Article  CAS  PubMed  Google Scholar 

  • Hoang PH, Landi MT (2022) DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors. Cancers (Basel) 14(4)

    Google Scholar 

  • Hollings N, Shaw P (2002) Diagnostic imaging of lung cancer. Eur Respir J 19(4):722–742

    Article  CAS  PubMed  Google Scholar 

  • Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, Stahel R (2003) Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10(3):356–364

    Article  CAS  PubMed  Google Scholar 

  • Hosgood HD 3rd, Sapkota AR, Rothman N, Rohan T, Hu W, Xu J, Vermeulen R, He X, White JR, Wu G et al (2014) The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ Mol Mutagen 55(8):643–651

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jairam V, Park HS (2019) Strengths and limitations of large databases in lung cancer radiation oncology research. Transl Lung Cancer Res 8(Suppl 2):S172–S183

    Article  PubMed  PubMed Central  Google Scholar 

  • Jensen MA, Ferretti V, Grossman RL, Staudt LM (2017) The NCI Genomic Data Commons as an engine for precision medicine. Blood 130(4):453–459

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jiang M, Li X, Quan X, Li X, Zhou B (2018) Single nucleotide polymorphisms in HMGB1 correlate with lung cancer risk in the Northeast Chinese Han Population. Molecules 23(4)

    Google Scholar 

  • Jones GS, Baldwin DR (2018) Recent advances in the management of lung cancer. Clin Med (Lond) 18(Suppl 2):s41–s46

    Article  PubMed  Google Scholar 

  • Kadir T, Gleeson F (2018) Lung cancer prediction using machine learning and advanced imaging techniques. Transl Lung Cancer Res 7(3):304–312

    Article  PubMed  PubMed Central  Google Scholar 

  • Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP (2013) The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene 32(30):3559–3568

    Article  CAS  PubMed  Google Scholar 

  • Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P, Pazdur R (2016a) FDA Approval Summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 21(5):634–642

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P, Pazdur R (2016b) FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res 22(6):1307–1312

    Article  CAS  PubMed  Google Scholar 

  • Kazandjian D, Blumenthal GM, Luo L, He K, Fran I, Lemery S, Pazdur R (2016c) Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer. Oncologist 21(8):974–980

    Article  PubMed  PubMed Central  Google Scholar 

  • Khozin S, Blumenthal GM, Jiang X, He K, Boyd K, Murgo A, Justice R, Keegan P, Pazdur R: U.S. (2014) Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist 19(7):774–779

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E, Helms W, Leong R, Song P, Pan Y et al (2015) FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 21(11):2436–2439

    Article  CAS  PubMed  Google Scholar 

  • Khunger A, Khunger M, Velcheti V (2018) Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis 12:1753466618767611

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim YJ, Sertamo K, Pierrard MA, Mesmin C, Kim SY, Schlesser M, Berchem G, Domon B (2015) Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach. J Proteome Res 14(3):1412–1419

    Article  CAS  PubMed  Google Scholar 

  • Kim YI, Ahn JM, Sung HJ, Na SS, Hwang J, Kim Y, Cho JY (2016) Meta-markers for the differential diagnosis of lung cancer and lung disease. J Proteome 148:36–43

    Article  CAS  Google Scholar 

  • Kim J, Bradford D, Larkins E, Pai-Scherf LH, Chatterjee S, Mishra-Kalyani PS, Wearne E, Helms WS, Ayyoub A, Bi Y et al (2021) FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res 27(20):5452–5456

    Article  CAS  PubMed  Google Scholar 

  • Koch AL, Vellanki PJ, Drezner N, Li X, Mishra-Kalyani PS, Shen YL, Xia H, Li Y, Liu J, Zirkelbach JF et al (2021) FDA approval summary: osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative project Orbis review. Clin Cancer Res 27(24):6638–6643

    Article  CAS  PubMed  Google Scholar 

  • Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C (1999) Topotecan – a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56(1):1–12

    Article  CAS  PubMed  Google Scholar 

  • Kong J, Chen X, Wang J, Li J, Xu F, Gao S, Yu H, Qian B (2020) Genetic polymorphisms in the Vitamin D pathway and non-small cell lung cancer survival. Pathol Oncol Res 26(3):1709–1715

    Article  PubMed  Google Scholar 

  • Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S et al (2014) Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol 15(1):106–113

    Article  CAS  PubMed  Google Scholar 

  • Kumar R, Chaudhary K, Gupta S, Singh H, Kumar S, Gautam A, Kapoor P, Raghava GP (2013) CancerDR: cancer drug resistance database. Sci Rep 3:1445

    Article  PubMed  PubMed Central  Google Scholar 

  • Lababede O, Meziane MA (2018) The eighth edition of TNM staging of lung cancer: reference chart and diagrams. Oncologist 23(7):844–848

    Article  PubMed  PubMed Central  Google Scholar 

  • Langevin SM, Kratzke RA, Kelsey KT (2015) Epigenetics of lung cancer. Transl Res 165(1):74–90

    Article  CAS  PubMed  Google Scholar 

  • Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27(15):2530–2535

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G, Stephens O, Zahalka E, Ringgold K, Helms W et al (2016) FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib. Clin Cancer Res 22(21):5171–5176

    Article  CAS  PubMed  Google Scholar 

  • Laroumagne S, Salinas-Pineda A, Hermant C, Murris M, Gourraud PA, Do C, Segonds C, Didier A, Mazieres J (2011) Incidence and characteristics of bronchial colonisation in patient with lung cancer: a retrospective study of 388 cases. Rev Mal Respir 28(3):328–335

    Article  CAS  PubMed  Google Scholar 

  • Lawi ZK, Al-Shuhaib MBS, Amara IB (2022) The rs1801280 SNP is associated with non-small cell lung carcinoma by exhibiting a highly deleterious effect on N-acetyltransferase 2. J Cancer Res Clin Oncol

    Google Scholar 

  • Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H et al (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 27(12):2030–2037

    Article  CAS  PubMed  Google Scholar 

  • Lee SH, Sung JY, Yong D, Chun J, Kim SY, Song JH, Chung KS, Kim EY, Jung JY, Kang YA et al (2016) Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer 102:89–95

    Article  PubMed  Google Scholar 

  • Lee G, Park H, Bak SH, Lee HY (2020) Radiomics in lung cancer from basic to advanced: current status and future directions. Korean J Radiol 21(2):159–171

    Article  PubMed  PubMed Central  Google Scholar 

  • Li C, Lu H (2018) Adenosquamous carcinoma of the lung. Onco Targets Ther 11:4829–4835

    Article  PubMed  PubMed Central  Google Scholar 

  • Li LS, Kim H, Rhee H, Kim SH, Shin DH, Chung KY, Park KS, Paik YK, Chang J, Kim H (2004) Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 4(11):3394–3400

    Article  CAS  PubMed  Google Scholar 

  • Li Y, Zhang Y, Qiu F, Qiu Z (2011) Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis 32(15):1976–1983

    Article  CAS  PubMed  Google Scholar 

  • Li X, Li X, Yin Z, Jiang M, Tian W, Tang M, Zhou B (2019) Polymorphisms of rs4787050 and rs8045980 are associated with lung cancer risk in northeast Chinese female nonsmokers. Biomark Med 13(13):1119–1128

    Article  CAS  PubMed  Google Scholar 

  • Li W, Liu B, Wang W, Sun C, Che J, Yuan X, Zhai C (2022) Lung cancer stage prediction using multi-omics data. Comput Math Methods Med 2022:2279044

    PubMed  PubMed Central  Google Scholar 

  • Liu WB, Han F, Jiang X, Yang LJ, Li YH, Liu Y, Chen HQ, Ao L, Cui ZH, Cao J et al (2012) ANKRD18A as a novel epigenetic regulation gene in lung cancer. Biochem Biophys Res Commun 429(3–4):180–185

    Article  CAS  PubMed  Google Scholar 

  • Liu SH, Shen PC, Chen CY, Hsu AN, Cho YC, Lai YL, Chen FH, Li CY, Wang SC, Chen M et al (2020) DriverDBv3: a multi-omics database for cancer driver gene research. Nucleic Acids Res 48(D1):D863–D870

    CAS  PubMed  Google Scholar 

  • Liu Y, Liang X, Zhang H, Dong J, Zhang Y, Wang J, Li C, Xin X, Li Y (2022) ER Stress-related genes EIF2AK3, HSPA5, and DDIT3 polymorphisms are associated with risk of lung cancer. Front Genet 13:938787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Loehrer PJ Sr, Einhorn LH, Greco FA (1988) Cisplatin plus etoposide in small cell lung cancer. Semin Oncol 15(3 Suppl 3):2–8

    PubMed  Google Scholar 

  • Lopez-Sanchez LM, Jurado-Gamez B, Feu-Collado N, Valverde A, Canas A, Fernandez-Rueda JL, Aranda E, Rodriguez-Ariza A (2017) Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. Am J Physiol Lung Cell Mol Physiol 313(4):L664–L676

    Article  PubMed  Google Scholar 

  • Louis E, Adriaensens P, Guedens W, Bigirumurame T, Baeten K, Vanhove K, Vandeurzen K, Darquennes K, Vansteenkiste J, Dooms C et al (2016) Detection of lung cancer through metabolic changes measured in blood plasma. J Thorac Oncol 11(4):516–523

    Article  PubMed  Google Scholar 

  • Lu M, Zhan X (2018) The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J 9(1):77–102

    Article  PubMed  PubMed Central  Google Scholar 

  • Lu C, Onn A, Vaporciyan AA (2017) Chapter 84: cancer of the Lung. In: Holland-Frei cancer medicine, 9th edn. Wiley Blackwell. ISBN 9781119000846

    Google Scholar 

  • Ma L, Muscat JE, Sinha R, Sun D, Xiu G (2021a) Proteomics of exhaled breath condensate in lung cancer and controls using data-independent acquisition (DIA): a pilot study. J Breath Res 15(2)

    Google Scholar 

  • Ma Y, Qiu M, Wang S, Meng S, Yang F, Jiang G (2021b) Distinct tumor bacterial microbiome in lung adenocarcinomas manifested as radiological subsolid nodules. Transl Oncol 14(6):101050

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Madama D, Martins R, Pires AS, Botelho MF, Alves MG, Abrantes AM, Cordeiro CR (2021) Metabolomic profiling in lung cancer: a systematic review. Meta 11(9)

    Google Scholar 

  • Majumdar S, Saha S (2020) Systems immunology approach in understanding the association of allergy and cancer. In: Singh S (ed) Systems and synthetic immunology. Springer, Singapore

    Google Scholar 

  • Martinez-Jimenez F, Muinos F, Sentis I, Deu-Pons J, Reyes-Salazar I, Arnedo-Pac C, Mularoni L, Pich O, Bonet J, Kranas H et al (2020) A compendium of mutational cancer driver genes. Nat Rev Cancer 20(10):555–572

    Article  CAS  PubMed  Google Scholar 

  • Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X, Rodriguez L, Mishra-Kalyani P, Goldberg KB, Kluetz PG et al (2021) FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist 26(5):433–438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mathieu LN, Larkins E, Akinboro O, Roy P, Amatya AK, Fiero MH, Mishra-Kalyani PS, Helms WS, Myers CE, Skinner AM et al (2022) FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations. Clin Cancer Res 28(2):249–254

    Article  CAS  PubMed  Google Scholar 

  • McNitt-Gray MF, Armato SG 3rd, Meyer CR, Reeves AP, McLennan G, Pais RC, Freymann J, Brown MS, Engelmann RM, Bland PH et al (2007) The Lung Image Database Consortium (LIDC) data collection process for nodule detection and annotation. Acad Radiol 14(12):1464–1474

    Article  PubMed  PubMed Central  Google Scholar 

  • Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H et al (2013) MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res 19(19):5423–5433

    Article  CAS  PubMed  Google Scholar 

  • Meng YQ, Shi Q, Zhu SJ, He GH, Zhang SJ, Sun C (2021) Asbestos-induced lung cancer-associated SNP rs13383928 regulates PTH2R expression in lung tissue. Hum Hered:1–5

    Google Scholar 

  • Michelotti A, de Scordilli M, Bertoli E, De Carlo E, Del Conte A, Bearz A (2022) NSCLC as the paradigm of precision medicine at its finest: the rise of new druggable molecular targets for advanced disease. Int J Mol Sci 23(12)

    Google Scholar 

  • Miele E, Spinelli GP, Miele E, Tomao F, Tomao S (2009) Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 4:99–105

    CAS  PubMed  PubMed Central  Google Scholar 

  • Minguet J, Smith KH, Bramlage P (2016) Targeted therapies for treatment of non-small cell lung cancer--recent advances and future perspectives. Int J Cancer 138(11):2549–2561

    Article  CAS  PubMed  Google Scholar 

  • Mur LA, Huws SA, Cameron SJ, Lewis PD, Lewis KE (2018) Lung cancer: a new frontier for microbiome research and clinical translation. Ecancermedicalscience 12:866

    Article  PubMed  PubMed Central  Google Scholar 

  • Najafi Z, Mohamadnia A, Ahmadi R, Mahmoudi M, Bahrami N, Khosravi A, Jamaati H, Tabarsi P, Kazem Pour Dizaji M, Shirian S (2020) Proteomic and genomic biomarkers for non-small cell lung cancer: peroxiredoxin, haptoglobin, and alpha-1 antitrypsin. Cancer Med 9(11):3974–3982

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E et al (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(12):1655–1669

    Article  CAS  PubMed  Google Scholar 

  • Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, Bi Y, Liu J, Rahman A, Wearne E et al (2022) FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res 28(8):1482–1486

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S et al (2022) The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol 17(3):362–387

    Article  PubMed  Google Scholar 

  • Nobili S, Lavacchi D, Perrone G, Vicini G, Tassi R, Landini I, Grosso A, Roviello G, Mazzanti R, Santomaggio C et al (2020) Vinorelbine in non-small cell lung cancer: real-world data from a single-institution experience. Oncol Res 28(3):237–248

    Article  PubMed  PubMed Central  Google Scholar 

  • Nooreldeen R, Bach H (2021) Current and future development in lung cancer diagnosis. Int J Mol Sci 22(16)

    Google Scholar 

  • Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg KB, Griffin N, Bijwaard K, Lee EY, Philip R, Jiang X et al (2018) FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist 23(6):740–745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Olivier T, Prasad V (2022) Amivantamab and mobocertinib in exon 20 insertions EGFR mutant lung cancer, challenge to the current guidelines. Transl Oncol 23:101475

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, Van Criekinge W (2008) PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 36(Database issue):D842–D846

    CAS  PubMed  Google Scholar 

  • Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyani PS, He K, Zhao H, Yu J, Paciga M, Goldberg KB et al (2017) FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist 22(11):1392–1399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Panunzio A, Sartori P (2020) Lung cancer and radiological imaging. Curr Radiopharm 13(3):238–242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Parashar B, Arora S, Wernicke AG (2013) Radiation therapy for early stage lung cancer. Semin Intervent Radiol 30(2):185–190

    Article  PubMed  PubMed Central  Google Scholar 

  • Patel S, Petty WJ, Sands JM (2021) An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer. Ther Adv Med Oncol 13:17588359211020529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pedersen S, Hansen JB, Maltesen RG, Szejniuk WM, Andreassen T, Falkmer U, Kristensen SR (2021) Identifying metabolic alterations in newly diagnosed small cell lung cancer patients. Metabol Open 12:100127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pircher A, Wasle IK, Mian M, Gamerith G, Ulsperger E, Studnicka M, Mohn-Staudner A, Hilbe W, Fiegl M (2013) Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement. Anticancer Res 33(9):3831–3836

    CAS  PubMed  Google Scholar 

  • Purandare NC, Rangarajan V (2015) Imaging of lung cancer: implications on staging and management. Indian J Radiol Imaging 25(2):109–120

    Article  PubMed  PubMed Central  Google Scholar 

  • Ren Y, Zhao S, Jiang D, Feng X, Zhang Y, Wei Z, Wang Z, Zhang W, Zhou QF, Li Y et al (2018) Proteomic biomarkers for lung cancer progression. Biomark Med 12(3):205–215

    Article  CAS  PubMed  Google Scholar 

  • Repana D, Nulsen J, Dressler L, Bortolomeazzi M, Venkata SK, Tourna A, Yakovleva A, Palmieri T, Ciccarelli FD (2019) The Network of Cancer Genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens. Genome Biol 20(1):1

    Article  PubMed  PubMed Central  Google Scholar 

  • Rho JH, Roehrl MH, Wang JY (2009) Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J Proteome Res 8(12):5610–5618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6(1):1–6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Richardson CJ, Gao Q, Mitsopoulous C, Zvelebil M, Pearl LH, Pearl FM (2009) MoKCa database--mutations of kinases in cancer. Nucleic Acids Res 37(Database issue):D824–D831

    Article  CAS  PubMed  Google Scholar 

  • Rijavec E, Biello F, Indini A, Grossi F, Genova C (2022) Current insights on the treatment of anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer: focus on brigatinib. Clin Pharmacol 14:1–9

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rocha CM, Carrola J, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L et al (2011) Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res 10(9):4314–4324

    Article  CAS  PubMed  Google Scholar 

  • Ruan X, Ye Y, Cheng W, Xu L, Huang M, Chen Y, Zhu J, Lu X, Yan F (2022) Multi-omics integrative analysis of lung adenocarcinoma: an in silico profiling for precise medicine. Front Med (Lausanne) 9:894338

    Article  PubMed  Google Scholar 

  • Rutledge MR, Waddell JA, Solimando DA Jr (2014) Irinotecan and Carboplatin (IC) regimen for small-cell lung cancer and non-small-cell lung cancer. Hosp Pharm 49(7):603–611

    Article  PubMed  PubMed Central  Google Scholar 

  • Santarelli L, Gaetani S, Monaco F, Bracci M, Valentino M, Amati M, Rubini C, Sabbatini A, Pasquini E, Zanotta N et al (2019) Four-miRNA signature to identify asbestos-related lung malignancies. Cancer Epidemiol Biomark Prev 28(1):119–126

    Article  CAS  Google Scholar 

  • Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A, Flemming N, Seemann S, Distler J, Lewin J et al (2010) SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 10:600

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scott LJ (2018) Osimertinib as first-line therapy in advanced NSCLC: a profile of its use. Drugs Ther Perspect 34(8):351–357

    Article  PubMed  PubMed Central  Google Scholar 

  • Scott A, Salgia R (2008) Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med 2(6):577–586

    Article  CAS  PubMed  Google Scholar 

  • Sellers K, Allen TD, Bousamra M 2nd, Tan J, Mendez-Lucas A, Lin W, Bah N, Chernyavskaya Y, MacRae JI, Higashi RM et al (2019) Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes. Br J Cancer 121(1):51–64

    Article  PubMed  PubMed Central  Google Scholar 

  • Shaikh FJ, Rao DS (2022) Prediction of cancer disease using machine learning approach. Mater Today Proc 50:40–47

    Article  Google Scholar 

  • Shen Y, Yao H, Li A, Wang M (2016) CSCdb: a cancer stem cells portal for markers, related genes and functional information. Database (Oxford) 2016

    Google Scholar 

  • Shen N, Du J, Zhou H, Chen N, Pan Y, Hoheisel JD, Jiang Z, Xiao L, Tao Y, Mo X (2019) A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma. Front Oncol 9:1281

    Article  PubMed  PubMed Central  Google Scholar 

  • Shi YX, Wang Y, Li X, Zhang W, Zhou HH, Yin JY, Liu ZQ (2017) Genome-wide DNA methylation profiling reveals novel epigenetic signatures in squamous cell lung cancer. BMC Genomics 18(1):901

    Article  PubMed  PubMed Central  Google Scholar 

  • Shirley M (2018) Dacomitinib: first global approval. Drugs 78(18):1947–1953

    Article  PubMed  Google Scholar 

  • Sim Y, Chung MJ, Kotter E, Yune S, Kim M, Do S, Han K, Kim H, Yang S, Lee DJ et al (2020) Deep convolutional neural network-based software improves radiologist detection of malignant lung nodules on chest radiographs. Radiology 294(1):199–209

    Article  PubMed  Google Scholar 

  • Su L, Huang H, Gao M, Li Y, Shi R, Chen C, Li X, Zhu G, Liu H, Chen J (2022) Association of CDH1, FANCB and APC gene polymorphisms with lung cancer susceptibility in Chinese Population. Zhongguo Fei Ai Za Zhi 25(9):658–664

    PubMed  Google Scholar 

  • Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R (2016) FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21(5):643–650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sulewska A, Niklinski J, Charkiewicz R, Karabowicz P, Biecek P, Baniecki H, Kowalczuk O, Kozlowski M, Modzelewska P, Majewski P et al (2022) A signature of 14 long non-coding RNAs (lncRNAs) as a step towards precision diagnosis for NSCLC. Cancers (Basel) 14(2)

    Google Scholar 

  • Sun X, Yi J, Yang J, Han Y, Qian X, Liu Y, Li J, Lu B, Zhang J, Pan X et al (2021) An integrated epigenomic-transcriptomic landscape of lung cancer reveals novel methylation driver genes of diagnostic and therapeutic relevance. Theranostics 11(11):5346–5364

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Szczyrek M, Mlak R, Szudy-Szczyrek A, Wojas-Krawczyk K, Kedziora K, Milanowski J (2022) Polymorphism of Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) can be associated with clinical outcome of non-small cell lung cancer. Cell 11(6)

    Google Scholar 

  • Takahashi S, Asada K, Takasawa K, Shimoyama R, Sakai A, Bolatkan A, Shinkai N, Kobayashi K, Komatsu M, Kaneko S et al (2020) Predicting deep learning based multi-omics parallel integration survival subtypes in lung cancer using reverse phase protein array data. Biomol Ther 10(10)

    Google Scholar 

  • Tam M, Dyer T, Dissez G, Morgan TN, Hughes M, Illes J, Rasalingham R, Rasalingham S (2021) Augmenting lung cancer diagnosis on chest radiographs: positioning artificial intelligence to improve radiologist performance. Clin Radiol 76(8):607–614

    Article  CAS  PubMed  Google Scholar 

  • Tan X, Li D, Huang P, Jian X, Wan H, Wang G, Li Y, Ouyang J, Lin Y, Xie L (2020) dbPepNeo: a manually curated database for human tumor neoantigen peptides. Database (Oxford) 2020

    Google Scholar 

  • Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E et al (2019) COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res 47(D1):D941–D947

    Article  CAS  PubMed  Google Scholar 

  • Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of Indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12(3)

    Google Scholar 

  • Valk K, Vooder T, Kolde R, Reintam MA, Petzold C, Vilo J, Metspalu A (2010) Gene expression profiles of non-small cell lung cancer: survival prediction and new biomarkers. Oncology 79(3–4):283–292

    Article  PubMed  Google Scholar 

  • Vellanki PJ, Mulkey F, Jaigirdar AA, Rodriguez L, Wang Y, Xu Y, Zhao H, Liu J, Howe G, Wang J et al (2021) FDA approval summary: nivolumab with ipilimumab and chemotherapy for metastatic non-small cell lung cancer, a collaborative project orbis review. Clin Cancer Res 27(13):3522–3527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang S, Zhang H, Cheng L, Evans C, Pan CX (2010) Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. Anticancer Res 30(11):4573–4578

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wang R, Feng N, Wang Y, Gao S, Zhang F, Qian Y, Gao M, Yu H, Zhou B, Qian B (2019) SNPs in LncRNA genes are associated with non-small cell lung cancer in a Chinese population. J Clin Lab Anal 33(4):e22858

    Article  PubMed  PubMed Central  Google Scholar 

  • Wang C, Yang D, Zhang X, Zhang X, Yang L, Wang P, Zhou W, Li H, Li Y, Nie H et al (2020) Association of PTEN gene SNPs rs2299939 with PFS in patients with small cell lung cancer treated with early radiotherapy. Front Genet 11:298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Watanabe K, Emoto N, Hamano E, Sunohara M, Kawakami M, Kage H, Kitano K, Nakajima J, Goto A, Fukayama M et al (2012) Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer 130(11):2580–2590

    Article  CAS  PubMed  Google Scholar 

  • Weissfeld JL, Lin Y, Lin HM, Kurland BF, Wilson DO, Fuhrman CR, Pennathur A, Romkes M, Nukui T, Yuan JM et al (2015) Lung cancer risk prediction using common SNPs located in GWAS-identified susceptibility regions. J Thorac Oncol 10(11):1538–1545

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu C, Jin X, Tsueng G, Afrasiabi C, Su AI (2016) BioGPS: building your own mash-up of gene annotations and expression profiles. Nucleic Acids Res 44(D1):D313–D316

    Article  CAS  PubMed  Google Scholar 

  • Xi S, Xu H, Shan J, Tao Y, Hong JA, Inchauste S, Zhang M, Kunst TF, Mercedes L, Schrump DS (2013) Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest 123(3):1241–1261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xiao S, Sun S, Long W, Kuang S, Liu Y, Huang H, Zhou J, Zhou Y, Lu X (2018) A meta-analytic review of the association between two common SNPs in miRNAs and lung cancer susceptibility. Onco Targets Ther 11:2419–2427

    Article  PubMed  PubMed Central  Google Scholar 

  • Xie B, Ding Q, Han H, Wu D (2013) miRCancer: a microRNA-cancer association database constructed by text mining on literature. Bioinformatics 29(5):638–644

    Article  CAS  PubMed  Google Scholar 

  • Xu H, Ma J, Wu J, Chen L, Sun F, Qu C, Zheng D, Xu S (2016) Gene expression profiling analysis of lung adenocarcinoma. Braz J Med Biol Res 49(3)

    Google Scholar 

  • Yan X, Yang M, Liu J, Gao R, Hu J, Li J, Zhang L, Shi Y, Guo H, Cheng J et al (2015) Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res 5(10):3111–3122

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yang Y, Zhao S, Fan Y, Zhao F, Liu Q, Hu W, Liu D, Fan K, Wang J, Wang J (2009) Detection and identification of potential biomarkers of non-small cell lung cancer. Technol Cancer Res Treat 8(6):455–466

    Article  CAS  PubMed  Google Scholar 

  • Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR et al (2013) Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41(Database issue):D955-961

    Google Scholar 

  • Yang D, Yang X, Li Y, Zhao P, Fu R, Ren T, Hu P, Wu Y, Yang H, Guo N (2020) Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal. J Transl Med 18(1):243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yardley DA (2013) nab-Paclitaxel mechanisms of action and delivery. J Control Release 170(3):365–372

    Article  CAS  PubMed  Google Scholar 

  • Yin J, Hou W, Vogel U, Ma Y, Wang C, Wang H, Sun Z (2020) Interaction between common variants of MDM2 and PPP1R13L and CD3EAP and TP53 SNPs in relation to lung cancer risk among Chinese. Ann Transl Med 8(15):934

    Article  PubMed  PubMed Central  Google Scholar 

  • Yun KM, Bazhenova LA (2022) Update on Lorlatinib: role in reducing the risk of disease progression in ALK-positive NSCLC. Cancer Manag Res 14:843–850

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yun Y, Wang Y, Yang E, Jing X (2022) Cuproptosis-Related Gene - SLC31A1, FDX1 and ATP7B - polymorphisms are associated with risk of lung cancer. Pharmgenomics Pers Med 15:733–742

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5(3):288–300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zeng GQ, Zhang PF, Deng X, Yu FL, Li C, Xu Y, Yi H, Li MY, Hu R, Zuo JH et al (2012) Identification of candidate biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics. Mol Cell Proteomics 11(6):M111 013946

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang J, Baran J, Cros A, Guberman JM, Haider S, Hsu J, Liang Y, Rivkin E, Wang J, Whitty B et al (2011) International Cancer Genome Consortium Data Portal--a one-stop shop for cancer genomics data. Database (Oxford) 2011:bar026

    Article  PubMed  Google Scholar 

  • Zhang XY, Zhang G, Jiang Y, Liu D, Li MZ, Zhong Q, Zeng SQ, Liu WL, Zeng MS (2015) The prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer. Chin J Cancer 34(8):335–349

    CAS  PubMed  Google Scholar 

  • Zhang Y, Zhang L, Li R, Chang DW, Ye Y, Minna JD, Roth JA, Han B, Wu X (2017) Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility. Ann Oncol 28(7):1625–1630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang C, Leng W, Sun C, Lu T, Chen Z, Men X, Wang Y, Wang G, Zhen B, Qin J (2018) Urine proteome profiling predicts lung cancer from control cases and other tumors. EBioMedicine 30:120–128

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang H, Li Y, Guo S, Wang Y, Wang H, Lu D, Wang J, Jin L, Jiang G, Wu J et al (2020a) Effect of ERCC2 rs13181 and rs1799793 polymorphisms and environmental factors on the prognosis of patients with lung cancer. Am J Transl Res 12(10):6941–6953

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang L, Zheng J, Ahmed R, Huang G, Reid J, Mandal R, Maksymuik A, Sitar DS, Tappia PS, Ramjiawan B et al (2020b) A high-performing plasma metabolite panel for early-stage lung cancer detection. Cancers (Basel) 12(3)

    Google Scholar 

  • Zhao Z, Fei K, Bai H, Wang Z, Duan J, Wang J (2021a) Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. Thorac Cancer 12(1):66–78

    Article  CAS  PubMed  Google Scholar 

  • Zhao Y, Gao Y, Xu X, Zhou J, Wang H (2021b) Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma. BMC Cancer 21(1):257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu L, Chen L (2019) Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett 24:40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu X, Luo H, Xu Y (2019) Transcriptome analysis reveals an important candidate gene involved in both nodal metastasis and prognosis in lung adenocarcinoma. Cell Biosci 9:92

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Sciences, Bose Institute, Kolkata, West Bengal, India

    Sudipto Saha & Sreyashi Majumdar

  2. Institute of Pulmocare & Research, Kolkata, West Bengal, India

    Parthasarathi Bhattacharyya

Authors
  1. Sudipto Saha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sreyashi Majumdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Parthasarathi Bhattacharyya
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Saha, S., Majumdar, S., Bhattacharyya, P. (2023). Lung Cancer. In: Pulmonomics: Omics Approaches for Understanding Pulmonary Diseases . Springer, Singapore. https://doi.org/10.1007/978-981-99-3505-5_15

Download citation

Publish with us

Policies and ethics

Search

Navigation